Most men who undergo stereotactic body radiation therapy (SBRT) for prostate cancer experience only mild long-term side effects, with severe complications occurring in a small minority. The side effects that do persist fall into three broad categories: urinary symptoms, bowel irritation, and changes in sexual function. Across multiple studies with follow-up stretching to five or more years, late severe urinary and bowel problems each affect roughly 1 to 9 percent of patients, though milder symptoms are more common and tend to fluctuate over time. The picture is reassuring overall, but it is also more nuanced than a simple “low risk” label suggests, particularly for men who enter treatment with pre-existing urinary trouble or who receive higher radiation doses.
Urinary Side Effects
Urinary symptoms are the most frequently reported long-term issue after prostate SBRT. These include increased urinary frequency, urgency, a weak stream, and occasionally blood in the urine. In general populations of SBRT patients, late urinary toxicity that a doctor would classify as moderate (grade 2, meaning symptoms that require medication or affect daily life) shows up in roughly a fifth to a third of men depending on the study and follow-up length. Severe urinary problems (grade 3, requiring a procedure like catheterization) are considerably rarer, typically in the range of about 2.5 to 7 percent at five years, with grade 4 or 5 events essentially absent across large series.
One comparative study placed five-year incidences of moderate-or-worse late urinary toxicity somewhere between 3 and 9 percent, with bowel toxicity between 0 and 4 percent. Those numbers come from analyses focused specifically on extreme hypofractionation schedules like the ones used in SBRT. The wide range reflects real differences in patient populations, dose levels, and how carefully toxicity is tracked.
Men who had a prior transurethral resection of the prostate (TURP) face a distinctly higher risk. One study of SBRT patients with a TURP history found that about half experienced late moderate urinary symptoms, and roughly 6 percent had severe toxicity. Blood in the urine was particularly common in this group, appearing in about half of patients at a mean of around 10 months after treatment.1Frontiers in Oncology. Urinary Morbidity in Men Treated With Stereotactic Body Radiation Therapy (SBRT) for Localized Prostate Cancer Following Transurethral Resection of the Prostate (TURP) A separate analysis confirmed the finding, showing that a TURP history tripled the odds of late urinary toxicity of grade 2 or higher after adjusting for other factors.2Clinical and Translational Radiation Oncology. Extreme hypofractionated stereotactic radiotherapy for localized prostate Cancer: Efficacy and late urinary toxicity according to transurethral resection of the prostate history
For men without a surgical history, the trajectory is more favorable. Urinary symptoms tend to flare in the first few weeks after treatment, settle down, and then occasionally recur in milder form months later. Most of these late symptoms respond to medication and resolve without a procedure.
Bowel Side Effects
Long-term bowel trouble after SBRT is less common than urinary trouble, and when it does occur it tends to be milder. The main symptom is rectal bleeding, sometimes accompanied by looser stools or increased urgency. In one large series of over 260 patients, late moderate rectal bleeding occurred in about 1.5 percent, and no one experienced severe rectal bleeding.3PubMed Central. Proctitis following stereotactic body radiation therapy for prostate cancer A comparative study looking at prostate-only SBRT found late severe gastrointestinal toxicity in about 1 percent of patients.4International Journal of Radiation Oncology*Biology*Physics. Acute and Late Adverse Effects of Prostate-Only or Pelvic Stereotactic Radiation Therapy in Prostate Cancer: A Comparative Study
Men on blood thinners or antiplatelet drugs deserve a closer look. In one cohort of patients on such medications at the time of SBRT, about 27 percent experienced minor late bleeding events. Clinically significant late bleeding was rare even in this group, with just one patient each experiencing moderate and severe hematuria that required treatment. About 39 percent had some blood in the stool at a median of six months, though this was mostly mild and self-limited.5Frontiers in Oncology. Bleeding Risk Following Stereotactic Body Radiation Therapy for Localized Prostate Cancer in Men on Baseline Anticoagulant or Antiplatelet Therapy
Part of the reason bowel side effects tend to be modest relates to the physics of the treatment. SBRT delivers radiation in just four or five sessions rather than the 40-odd sessions of conventional radiation. The large dose per fraction might sound more damaging, but because the prostate itself is thought to respond favorably to this scheduling while surrounding tissues like the rectum and bladder respond similarly to conventional dosing, the net effect is less total radiation exposure to those neighboring structures.6Frontiers in Oncology. Quality of Life and Toxicity after SBRT for Organ-Confined Prostate Cancer, a 7-Year Study
Sexual Function Changes
SBRT’s effect on sexual function is real but gradual, and in many men partial rather than total. Studies consistently show a slow decline in erectile function over the first two to five years, rather than the abrupt loss that often follows surgery. In one study of men who were potent before treatment, about 78 percent still had erections sufficient for intercourse at two years, though the proportion meeting a stricter definition of “potent” dropped from 100 percent at baseline to about 54 percent over the same period.7PubMed Central. Potency preservation following stereotactic body radiation therapy for prostate cancer At five years, about 45 percent of men who had functional erections at baseline retained that function.8PubMed. Erectile function after stereotactic body radiotherapy for localized prostate cancer
The use of sexual aids increased from about 36 percent at baseline to 49 percent at two years in the same cohort, which suggests that many men adapted rather than accepted a complete loss of sexual activity.7PubMed Central. Potency preservation following stereotactic body radiation therapy for prostate cancer The gradual nature of the decline also means that men and their partners have time to adjust, try medications, and explore other options in a way that an overnight change after surgery does not allow.
How SBRT Compares to Surgery
Men often weigh SBRT against radical prostatectomy, and the side-effect tradeoffs are genuinely different rather than one being universally better. The PACE-A randomized trial provided some of the clearest direct comparisons. At two years, half of the surgery patients were using at least one urinary pad daily compared with about 7 percent of the SBRT patients. Sexual function scores were substantially better in the SBRT group. Bowel scores, however, tilted the other way: surgery patients reported better bowel function than SBRT patients, though the absolute difference was modest.9European Urology. Radical Prostatectomy Versus Stereotactic Radiotherapy for Clinically Localised Prostate Cancer: Results of the PACE-A Randomised Trial
An earlier quality-of-life comparison echoed this pattern. The biggest divergences appeared in the first six months: surgery caused larger drops in urinary and sexual quality of life, while SBRT caused a larger dip in bowel quality of life. Over the longer term, urinary and sexual quality of life remained clinically worse after surgery but not after SBRT, while the bowel differences largely evened out.10PubMed Central. Comparison of quality of life after stereotactic body radiotherapy and surgery for early-stage prostate cancer
The short version: SBRT tends to preserve continence and sexual function better than surgery, at the cost of a small increase in bowel irritation. Most men find the bowel symptoms manageable, but anyone who already has significant bowel disease should factor that in.
How SBRT Compares to Conventional Radiation
Comparing SBRT to standard intensity-modulated radiation therapy (IMRT) is trickier because the two approaches use very different schedules. One large claims-based analysis found that SBRT patients had modestly higher rates of urinary toxicity than IMRT patients at both 6 months and 24 months. The difference was statistically significant, with about 44 percent of SBRT patients experiencing some urinary claim compared with 36 percent of IMRT patients at two years.11PubMed Central. Stereotactic Body Radiation Therapy Versus Intensity-Modulated Radiation Therapy for Prostate Cancer: Comparison of Toxicity
A different matched analysis, however, found no significant differences in composite urinary, bowel, or erectile dysfunction outcomes between SBRT and IMRT, with one exception: a slightly higher risk of urinary fistula with SBRT (about 1 percent versus 0.1 percent at two years). That same study noted that SBRT was meaningfully less expensive, with average radiation costs about $8,000 lower than IMRT.12PubMed Central. Comparative Toxicities and Cost of Intensity-Modulated Radiotherapy, Proton Radiation, and Stereotactic Body Radiotherapy Among Younger Men With Prostate Cancer
The discrepancy between these studies probably reflects differences in how toxicity was measured (insurance claims versus clinical grading), the patient populations involved, and the specific SBRT doses used. On balance, SBRT and conventional IMRT appear to produce broadly similar long-term side-effect profiles, with SBRT requiring far fewer treatment visits and costing less out of pocket.
Who Faces Higher Risk
Not every patient starts from the same baseline, and pre-treatment urinary health is the single most consistent predictor of who will have more trouble after SBRT. Men with high baseline symptom scores (specifically, those reporting significant urinary urgency or straining before treatment) face elevated odds of late urinary toxicity. One study found that each one-point increase in baseline urgency roughly doubled the odds of a late urinary problem.13PubMed Central. Urinary Outcomes for Men With High Baseline International Prostate Symptom Scores Treated With Prostate SBRT
That does not mean men with bothersome urinary symptoms at baseline cannot receive SBRT. A study specifically looking at men with high symptom scores found that most still improved or stabilized after treatment, and the rate of severe toxicity requiring intervention was about 7.5 percent over three years.14Frontiers in Oncology. Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer in Men With a High Baseline International Prostate Symptom Score (IPSS ≥ 15) The key is that these men need careful counseling about the higher probability of needing medications or procedures afterward, and their expectations should be calibrated accordingly.
Prostate size also plays a role. Larger prostates receive more total radiation exposure to the urethra running through them, and some series have flagged prostate volume as a contributor to late toxicity. Prior prostate procedures, as discussed above, are another clear red flag.
Whether Dose Level Matters
SBRT for prostate cancer typically delivers somewhere between 35 and 40 Gy across four or five fractions. Whether pushing toward the higher end of that range increases long-term side effects has been a subject of active investigation, and the evidence is somewhat mixed.
One phase 1/2 dose-escalation study found that the two-year rate of moderate late urinary toxicity climbed from 21 percent at 35 Gy to 42 percent at 40 Gy, a statistically significant increase. Bowel toxicity also varied but less consistently.15PubMed. Increased toxicities associated with dose escalation of stereotactic body radiation therapy in prostate cancer: results from a phase I/II study By contrast, a separate long-term phase 1 study found that higher dose levels were not associated with higher rates of late moderate-or-worse bowel or urinary toxicity.16PubMed Central. Long-term Outcomes from a Phase 1 Dose Escalation Study Using Stereotactic Body Radiotherapy for Patients with Low- or Intermediate-risk Prostate Cancer
The disagreement likely stems from differences in patient selection, planning techniques, and how tightly radiation was conformed to the prostate versus surrounding tissues. A comprehensive review noted that side effects after SBRT are driven by both dosimetric factors (how much radiation hits the bladder, urethra, and rectum) and non-dosimetric factors (baseline symptoms, prostate size, prior procedures).17PubMed Central. Prostate Stereotactic Body Radiation Therapy: An Overview of Toxicity and Dose Response In practice, this means that a higher prescribed dose does not automatically translate to more side effects if the treatment plan keeps radiation tightly away from critical structures.
The Role of Hydrogel Spacers
To reduce rectal radiation exposure, some patients receive an injectable hydrogel spacer between the prostate and the rectum before SBRT. The gel pushes the rectal wall farther from the radiation target, and it dissolves on its own within several months. The idea makes intuitive physical sense, and it does reliably reduce the radiation dose reaching the rectum.
Whether that dose reduction translates into meaningfully fewer long-term side effects in the SBRT setting is less clear-cut. A systematic review of spacer use with SBRT found that late moderate bowel toxicity occurred in about 2.3 percent of spacer patients, with severe bowel toxicity at about 0.3 percent.18PubMed Central. SpaceOAR hydrogel spacer injection prior to stereotactic body radiation therapy for men with localized prostate cancer: A systematic review Those are low numbers, but bowel toxicity after SBRT is already quite low without a spacer, which makes it hard to show a statistically significant benefit.
One comparative study found that the spacer group had significantly less acute bowel toxicity (16 percent versus 28 percent), but the reduction in late bowel toxicity was smaller and did not reach statistical significance (4 percent versus 10 percent).19Frontiers in Oncology. Rectal Radiation Dose and Clinical Outcomes in Prostate Cancer Patients Treated With Stereotactic Body Radiation Therapy With and Without Hydrogel Another recent comparative study found no significant difference in late rectal or urinary toxicity between spacer and non-spacer groups.20Advances in Radiation Oncology. Hydrogel Spacer Insertion Prior to Stereotactic Body Radiation Therapy to the Prostate: A Comparative Study
The spacer appears to offer its clearest benefit during the acute phase, and it may provide a margin of safety for men receiving higher doses or those whose anatomy places the rectum close to the prostate. For the typical patient receiving a standard SBRT dose, the evidence for a dramatic reduction in long-term bowel problems is modest at best. Whether the added procedure and cost are worth it is worth discussing with your radiation oncologist, especially if your anatomy is favorable to begin with.
When Hormone Therapy Is Added
Men with intermediate- or high-risk prostate cancer often receive androgen deprivation therapy (ADT) alongside SBRT. ADT shrinks the prostate and improves cancer control, but it comes with its own side effects, and combining it with radiation amplifies the overall toxicity burden. A review of this combination found that men receiving SBRT plus ADT had substantially higher rates of acute side effects across multiple domains: gastrointestinal, urinary, sexual, hormonal, and metabolic symptoms all rose significantly compared with SBRT alone. The rate of severe acute adverse events was about 12 percent with the combination versus 2 percent with radiation alone.21PubMed Central. Enhancing Androgen Deprivation Therapy (ADT) integration in prostate cancer: Insights for Stereotactic Body Radiotherapy (SBRT) and brachytherapy modalities
ADT-related side effects (hot flashes, fatigue, loss of libido, weight gain, bone thinning) are distinct from radiation side effects and typically improve after the hormone treatment ends, though some effects on body composition and bone density can linger. For men whose cancer biology warrants ADT, the added toxicity is generally accepted as a worthwhile tradeoff for better disease control, but it is important to understand that the side-effect experience of “SBRT plus hormones” is meaningfully different from “SBRT alone.”
Secondary Cancer Risk
Any form of radiation therapy carries a theoretical risk of causing a new cancer in the irradiated area years later. For prostate SBRT, the data on this question are reassuring, and in some analyses SBRT looks better than conventional radiation. A dosimetric modeling study found that SBRT plans produced lower estimated second cancer risks in nearby organs like the rectum and pelvic bone compared with conventional IMRT and older three-dimensional techniques.22Journal of Radiation Research. Secondary cancer risk from modern external-beam radiotherapy of prostate cancer patients: Impact of fractionation and dose distribution Another physics-based analysis confirmed that SBRT resulted in lower second cancer risks at all modeled sites relative to standard plans, though the absolute differences were very small, underscoring that the baseline risk from any modern technique is low.23Physics in Medicine & Biology. Radiation-induced second primary cancer risks from modern external beam radiotherapy for early prostate cancer: impact of stereotactic ablative radiotherapy (SABR), volumetric modulated arc therapy (VMAT) and flattening filter free (FFF) radiotherapy
Moving from modeling to real patient data, a propensity-score-adjusted analysis using a national cancer database found that SBRT was associated with about 22 percent lower odds of a second malignancy compared with conventionally fractionated IMRT.24Radiotherapy and Oncology. Second malignancy probabilities in prostate cancer patients treated with SBRT and other contemporary radiation techniques The comparison with surgery showed a similar direction but did not reach statistical significance. These findings make sense physically: SBRT treats a smaller volume of normal tissue and finishes in fewer sessions, which limits the low-dose bath that drives second cancer risk in conventional radiation.
MRI Guidance and Motion Management
One factor that is increasingly recognized as relevant to long-term outcomes is how well the prostate stays in position during each treatment session. The prostate can shift by several millimeters due to bladder filling and rectal gas, and if the treatment beam does not track those movements, nearby healthy tissue absorbs more radiation than planned.
Data from the MRI-guided arm of the MIRAGE trial showed that when the prostate drifted during treatment, particularly in the direction of the rectum, rates of acute moderate urinary toxicity climbed substantially. Patients whose prostate moved toward the inferior-posterior direction had a markedly higher rate of grade 2 urinary toxicity compared with those whose prostate stayed put.25International Journal of Radiation Oncology*Biology*Physics. Quantifying Intrafraction Motion and the Impact of Gating for Magnetic Resonance Imaging-Guided Stereotactic Radiation therapy for Prostate Cancer: Analysis of the Magnetic Resonance Imaging Arm From the MIRAGE Phase 3 Randomized Trial Gating, which pauses the beam whenever the prostate moves out of a predefined zone, is one strategy to address this. Real-time MRI guidance allows clinicians to see the prostate continuously and gate the beam accordingly. These technologies are still rolling out across treatment centers, but they represent a meaningful lever for reducing the side effects that stem from anatomical uncertainty rather than from the radiation dose itself.
What Happens If Cancer Recurs and Re-Irradiation Is Needed
A scenario that rarely comes up in initial treatment discussions but matters for long-term planning is what happens if the cancer comes back in the prostate after SBRT. Re-irradiating a previously treated area is possible but carries significantly higher risks. One salvage re-irradiation study noted an extremely high incidence of late severe rectal toxicity, comparable to what was seen in dose-escalation studies that delivered very high total doses to normal tissue.26PubMed Central. Salvage reirradiation for local failure of prostate cancer after curative radiation therapy: Association of rectal toxicity with dose distribution and normal-tissue complication probability models
This does not mean re-irradiation is off the table, but it does mean that the bowel and bladder tissues retain a “memory” of prior radiation, and adding more pushes them closer to their tolerance limits. Focal treatments like high-intensity focused ultrasound or cryotherapy may be preferred as salvage options in some cases. For men choosing between SBRT and surgery as their initial treatment, the ease or difficulty of salvage therapy after a potential recurrence is worth discussing up front, since surgical salvage after radiation is technically more challenging than radiation after surgery.
Financial and Practical Burden
Side effects carry costs beyond the physical symptoms. Follow-up visits, medications for urinary or bowel symptoms, erectile dysfunction drugs, and occasional procedures all add up. A review of financial toxicity in prostate cancer treatment found that greater out-of-pocket and indirect costs were inversely correlated with health-related quality of life, including prostate-specific domains like urinary, bowel, and sexual function.27PubMed Central. Financial toxicity associated with treatment of localized prostate cancer Men who experienced unanticipated side effects were more likely to feel dissatisfied with their treatment choice, and that dissatisfaction itself contributed to poorer quality-of-life scores.
SBRT has a structural advantage here in that it requires only four or five treatment visits rather than weeks of daily trips for conventional radiation. That translates to less time off work, fewer transportation costs, and less caregiver burden during the active treatment phase. The long-term supportive care costs depend on whether side effects develop and how persistent they are, which loops back to the risk factors discussed earlier. Men who enter treatment with good baseline urinary function and a standard-sized prostate tend to need less follow-up intervention and incur lower ongoing costs.